WntResearch Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Per Goran Norlen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	4.9yrs
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO

Per Goran Norlen (54 yo)

less than a year

Tenure

Dr. Per Goran Oskar Norlen, MD, PhD, serves as Chief Executive Officer of WntResearch AB from January, 2024. He served as Chief Executive Officer at Evaxion Biotech A/S since joined in October 3, 2022. He...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Andersson	Founder	17.8yrs	SEK 572.00k	0.0017% SEK 103.4
Per Goran Norlen	Chief Executive Officer	less than a year	no data	no data
Anders Tidfors	Chief Financial Officer	4yrs	no data	0.0017% SEK 104.0
Kicki Johansson	Chief Operating Officer	1.8yrs	no data	no data
Dennis Henriksen	Chief Technical Officer	8.3yrs	SEK 418.81k	no data
Klaus Christensen	Chief Commercial Officer	5.8yrs	no data	0.0013% SEK 77.7

4.9yrs

Average Tenure

61yo

Average Age

Experienced Management: WNT's management team is considered experienced (4.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Andersson	Founder	16.8yrs	SEK 572.00k	0.0017% SEK 103.4
Peter Strom	Director	9.8yrs	SEK 197.13k	0.012% SEK 690.2
Jan Vermorken	Scientific Advisor	no data	no data	no data
Asa Kornfeld	Director	less than a year	no data	no data
Ramon Salazar	Scientific Advisor	no data	no data	no data
Joachim Gullbo	Scientific Advisors	1.4yrs	no data	no data
Christer Nordstedt	Chairman of the board	2.8yrs	no data	0.0033% SEK 197.8
Gudrun Anstrén	Director	5.8yrs	no data	0.0016% SEK 95.0
Janna Sand-Dejmek	Director	4.3yrs	no data	0.00091% SEK 54.4
Andres Cervantes	Scientific Advisor	no data	no data	no data
Mats Lindskog	Member	1.5yrs	no data	0.00040% SEK 23.9

3.6yrs

Average Tenure

68yo

Average Age

Experienced Board: WNT's board of directors are considered experienced (3.6 years average tenure).

WntResearch Management

Management criteria checks 2/4

Key information

Recent management updates

No independent directors

WntResearch AB, Annual General Meeting, May 15, 2024

Chief Executive Officer exercised options to buy kr95k worth of stock.

Founder recently sold kr115k worth of stock

WntResearch AB, Annual General Meeting, May 11, 2023

No independent directors

Recent updates

WntResearch AB to Report Q3, 2024 Results on Nov 21, 2024

Wntresearch Provides an Update on the Work in Progress to Safeguard the Interests of Shareholders and Company Values

New major risk - Market cap size

New minor risk - Financial position

WntResearch AB to Report Q2, 2024 Results on Aug 22, 2024

WntResearch Presents Ad H Holes Observations from the NeoFox Study at ESMO GI

No independent directors

WntResearch AB to Report Q3, 2024 Results on Jun 13, 2024

WntResearch AB, Annual General Meeting, May 15, 2024

WntResearch AB to Report Q1, 2024 Results on May 03, 2024

WntResearch AB Continues to the Next Step in the Phase 2 Study Neofox with the Highest Evaluated Dose of Foxy-5

WntResearch AB to Report Fiscal Year 2023 Results on Feb 29, 2024

WntResearch Continues to the Second Dose Group in Clinical Proof of Concept Study of Foxy-5

WntResearch AB to Report Q3, 2023 Results on Nov 16, 2023

Chief Executive Officer exercised options to buy kr95k worth of stock.

New major risk - Share price stability

WntResearch AB to Report Q2, 2023 Results on Aug 17, 2023

WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study

Founder recently sold kr115k worth of stock

WntResearch AB, Annual General Meeting, May 11, 2023

WntResearch AB has completed a Composite Units Offering in the amount of SEK 39.970796 million.

WntResearch AB to Report Fiscal Year 2022 Results on Feb 09, 2023

No independent directors

WntResearch AB to Report Q3, 2022 Results on Nov 17, 2022

WntResearch AB to Report Q2, 2022 Results on Aug 18, 2022

No independent directors

WntResearch AB to Report Q1, 2022 Results on May 05, 2022

WntResearch Announces Appointment of Pernilla Sandwall as CEO

WntResearch files a patent application for the treatment of Acute Myeloid Leukemia

WntResearch AB, Annual General Meeting, May 31, 2021

WntResearch AB, Annual General Meeting, May 06, 2021

New 90-day low: kr1.12

New 90-day low: kr1.43

WntResearch AB to Report Nine Months, 2021 Results on Nov 18, 2021

WntResearch Names Anders Tidfors as CFO

New 90-day low: kr1.43

WntResearch AB Announces Resignation of Per-Ola Forsberg as Chief Financial Officer

WntResearch AB Announces Executive Changes

WntResearch AB announced that it has received SEK 10 million in funding from Global Emerging Markets

New 90-day low: kr1.70

New 90-day low - kr2.00

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age